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Abstract 51 
Objectives 52 
Toxic serum cefepime trough concentrations are not well defined in the current literature.  53 
We aimed to define a more precise plasma trough concentration threshold for this antibiotic’s 54 
neurological toxicity and to identify patients at risk for developing neurotoxic side effects. 55 
Methods 56 
Retrospective study including all patients who underwent cefepime therapeutic drug 57 
monitoring (TDM) between 2013 and 2017. Patients with cefepime concentrations other than 58 
trough were excluded. The primary outcome was to assess the incidence of neurotoxicity and 59 
its relationship with cefepime plasma trough concentrations. Secondary outcomes were the 60 
relationship of renal function, cefepime daily dose, age, cerebral and general comorbidities 61 
with the occurrence of neurotoxicity. We also compared the mortality rate during 62 
hospitalisation in patients with and without neurotoxicity, and the possible impact of 63 
neuroprotective co-medications on the outcomes. 64 
Results 65 
Cefepime concentrations were determined in 584 patients. Among 319 patients with available 66 
trough concentrations included, the overall incidence of neurotoxicity was 23.2% (74 of 319 67 
patients). Higher cefepime plasma trough concentrations were significantly associated with 68 
risk of (no neurotoxicity 6.3 mg/L [IQR 4.1, 8.6] vs with neurotoxicity 21.6 mg/L [IQR 17.0, 69 
28.6],  p <0.001). Patients with presumed cefepime neurotoxicity had a significantly lower 70 
renal function ( eGFR 82.0 ml/min/1.73m2 [IQR 45.0, 105.0] vs 35.0 ml/min/1.73m2 [IQR 71 
23.3, 53.3], p<0.001),  and significantly higher in-hospital mortality  (19 (7.8%) vs 26 72 
(35.1%) patients, p<0.001).No neurotoxic side effects were seen below a trough 73 
concentration of 7.7 mg/L. Levels ≥ 38.1 mg/L always led to neurologic side effects.  74 
Conclusion 75 
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In patients with risk factors for cefepime neurotoxicity, such as renal insufficiency, TDM 76 
should be systematically performed, aiming at trough concentrations below 7.5 mg/L. 77 
 78 
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Introduction 101 
Cefepime serves as a treatment of choice in AmpC producers that do not harbour extended-102 
spectrum beta-lactamase enzymes (ESBLs), or carbapenemases which are able to hydrolyse 103 
the drug [1-3].   104 
Plasma cefepime trough concentrations are highly variable in critically ill patients, and those 105 
with renal failure are at risk of drug accumulation [4, 5]. The neurotoxic effects of cefepime 106 
were first reported in 1999 [6], and some case reports have emphasized the relationship of 107 
neurological side effect with renal insufficiency in patients receiving cefepime treatment [7-108 
10]. The pathophysiology of cefepime neurotoxicity is thought to be related to concentration-109 
dependent GABA-A receptor modulation [11]. 110 
Switzerland is among the major consumers of cefepim per capita in Europe [12]. In order to 111 
monitor and prevent toxicity of cefepime, Swiss hospitals have started to offer therapeutic 112 
drug monitoring (TDM) [13, 14] – our hospital starting in 2013.  113 
Specific therapeutic ranges, however, are still missing. Case series observing smaller 114 
numbers of patients with cefepime-associated neurotoxici y have failed to determine any 115 
concentration thresholds [15]. Two studies – both re rospective - were conducted to define a 116 
threshold at which cefepime trough concentrations are associated with an increased risk of 117 
neurotoxicity, and suggested these to be at 20 mg/L and 15-20 mg/L respectively [13, 14]. 118 
Both studies however examined only a small number of trough concentrations. 119 
The objectives of the present study were to define more stringent therapeutic ranges for 120 
cefepime and to identify patients at risk for developing cefepime-associated neurotoxicity.  121 
 122 
 123 
 124 
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Methods 126 
Study design, population and setting 127 
This single-centre retrospective cohort study was conducted at the University Hospital of 128 
Bern, Switzerland, a 1000-bed tertiary care centre. Patients ≥18 yearsi) hospitalised between 129 
1st January 2013, when cefepime TDM became routinely available, and 31st December 2017, 130 
and ii) who had at least one cefepime plasma concentration available during hospitalisation, 131 
were included. An Infectious Diseases (ID) specialist (BBF) and a specialist in Internal 132 
Medicine (LBP) independently reviewed all patient’s medical records for neurological 133 
symptoms and indicators of neurotoxicity (see Table S1, supplementary material and 134 
definitions below) , with additional spot checks bytwo ID specialists (CH, PJ) on 50 135 
randomly selected medical records. For patients with presumed neurotoxicity, the clinical and 136 
pharmacological data was independently reviewed by three clinical pharmacologists (LK, SB, 137 
MH) in order to confirm the causality assessment and to evaluate the role of potentially 138 
confounding co-medications. For each patient, demographic features and characteristics were 139 
collected. Data on time of cefepime application andconcentration measurement were cross-140 
checked. Specific attention was paid to the development of neurotoxicity in patients with 141 
known underlying structural or functional cerebral impairments.  142 
The study was approved by the ethics committee of the canton of Bern (KEK No 2018-143 
00330). 144 
 145 
Definitions and outcomes 146 
Potential neurotoxicity and/or neurologic symptoms occurring after three dose intervals of 147 
cefepime were documented according to the Common Terminology Criteria for Adverse 148 
Events [16] (Table S1, supplementary material), with the absence of any plausible alternative 149 
cause/co-medication for the symptoms. We additionally documented possible adverse 150 
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neurological effects based on the occurrence of neurological signs (altered mental status, 151 
depressed concentration of consciousness, confusion, aphasia, asterixis, myoclonus, dystonia, 152 
seizure, non-convulsive status epilepticus [NCSE], coma) occurring under cefepime therapy 153 
based on literature reviews and  case reports [15, 17-19]. A formal causality assessment 154 
between cefepime exposure and adverse neurologic events was performed using the WHO-155 
UMC system  [20], with trough levels closest to thesymptoms being double-checked .The 156 
presence of potentially confounding medications that might have prevented convulsions  157 
(such as anticonvulsants, propofol and benzodiazepines) was examined for all patients with 158 
cefepime trough plasma concentrations ≥ 5mg/L [21, 27, 28]. In addition, adverse neurologic 159 
effects of these co-medications, that can not be distinguished from cefepime-associated 160 
neurotoxicity (e.g. altered mental status) were takn into account, and symptom improvement 161 
after stopping cefepime (i.e. positive de-challenge) was checked.The primary aim of this 162 
study was to assess the incidence of neurotoxicity and its relationship with cefepime plasma 163 
trough concentrations in patients receiving TDM. Secondary goals were to assess the 164 
correlation of i) renal function, ii) cefepime cumulative daily doses, iii) patient age, iv) 165 
comorbidities and v) centrally acting co-medications with neurotoxicity (see Table S2. We 166 
additionally reviewed mortality rates in these patien s and cause of death in patients with 167 
presumed cefepime neurotoxicity. 168 
 169 
Cefepime trough concentration measurements and estimation of creatinine clearance 170 
At our hospital, cefepime is given three times a day with dosing adjustment for patients with 171 
an eGFR of ≤ 50 ml/min/1.73m2 according to the manufacturer’s recommendations [21]. 172 
Continuous cefepime infusions are not administered. Institutional guidelines suggest 173 
application of high doses (2g every 8h) for patients with febrile neutropenia, meningitis or 174 
known Pseudomonas spp infections. 175 
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Sample preparation and analysis was performed as previously described [22, 23]. Samples 176 
from patients with sulfamethoxazole co-application were excluded from the study (n=4) due 177 
to potential interference.  178 
We only analysed confirmed cefepime plasma trough concentrations, defined as sample 179 
collection ≤ 1h before next dose application. The timing of blood collection and previous, as 180 
well as subsequent, cefepime administration were cafully cross-checked. In addition to 181 
plasma concentrations that were not confirmed trough concentrations, all results with unclear 182 
timing of cefepime application or concentration measurement were excluded. 183 
Dates of starting and stoping cefepime therapy, along with dosage of the drug over the 24 184 
hours preceding the cefepime measurement were record d. For patients with multiple 185 
cefepime measurements, we considered the highest cef pim  plasma trough concentration for 186 
statistical analysis. In patients with suspected neurotoxicity, we cross-checked the 187 
concentrations measured during the occurrence of neurological signs (see Figure S1 188 
supplementary material) . A detailed description of the methods (e.g. follow-up of patients) is 189 
presented in the supplementary materials. 190 
Renal function of the patients was assessed using the CKD-EPI formula for estimating the 191 
glomerular filtration rate (eGFR) on the day of cefepime concentration measurement [24]. If 192 
not available, the value of the closest day was considered. We also evaluated whether renal 193 
function was stable or not, based on the AKIN definitio  [25]. 194 
 195 
Statistical Analysis 196 
For comparison between those with and without neurotoxicity, the chi-squared test was used 197 
for categorical variables, and the Mann-Whitney-Wilcoxon test for continuous variables. 198 
Univariate and multivariate logistic regression models were fitted with neurotoxicity as 199 
dependent variable. The independent variables consisted of : 1) age, 2) sex, 3) kidney 200 
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function, 4) cefepime treatment duration until plasm  trough concentration measurement, 5) 201 
adjusted cefepime dose, 6) cefepime plasma concentratio , along with the following indicator 202 
variables : i) treatment of patient on intensive care unit (ICU) during hospitalisation, ii) 203 
general comorbidities (cardiovascular, pulmonary, diabetes, solid or haematological 204 
malignancy), and iii) neurologic comorbidities (arterial or venous thrombosis / haemorrhage, 205 
presence of a tumour, epilepsy, CNS infection, dementia, cognitive impairment, other brain 206 
diseases). The final adjusted multivariate model was determined by forwards and then 207 
backwards variable selection using the Akaike Information Criteria (AIC). The predictive 208 
power of the model was internally cross-validated using standard N-fold technique using 209 
bootstrapped data. (see supplementary material, model validation, Figure M1). 210 
Subgroup analyses were performed to identify whether t re was a significant difference in 211 
confounding co-medication between patients with andwithout adverse neurological effects. 212 
Results were considered significant at a p-value ≤ 0.05. The statistical analysis was 213 
performed using the R statistical software [26]. 214 
 215 
Results 216 
3793 patients were treated with cefepime between 2013 and 2017. General consent was 217 
available from 1845 patients. Of these, TDM was obtained in 548 and 1138 cefepime 218 
concentrations were available for assessment.  Among these patients, 265 were excluded, 219 
mainly because of inadequate/uncertain timing of the blood sampling, co-application of 220 
sulfamethoxazole (possible interference with cefepime concentration analysis) or lack of 221 
adequate neurological assessment (Figure S2, supplementary material). 222 
In total 319 patients were included in the analysis w th their respective highest recorded 223 
cefepime trough concentration. Seventy-four of the 319 included patients presented 224 
neurologic symptoms that were “possibly” related to cefepime administration according to 225 
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the formal WHO-UMC causality assessment. The most frequently encountered symptoms 226 
were confusion/agitation/hallucinations and reduced onsciousness, including coma (Table 227 
1). The median time from cefepime start to the development of neurologic signs was 2 days. 228 
In the vast majority of patients (96%), the cefepime treatment was adapted or stopped after 229 
the beginning of the symptoms. Eighty-one percent of the patients recovered at least partially 230 
from their symptoms, and required a median time of 2 days after therapy adaptation or 231 
cessation for the symptoms to improve or disappear. 232 
There was no significant difference in receiving at le st one potentially confounding centrally 233 
active co-medication between the two groups of patients (71/171 vs 28/74, p=0.69) (Table 234 
S4, supplemental material).  235 
Regarding the primary outcome of the study, cefepim plasma trough concentrations were 236 
significantly higher (21.6 mg/L [IQR 17.0,28.6] vs 6.3 mg/L[ IQR 4.1, 8.6] , p <0.001) in 237 
patients with suspected cefepime-associated neurotoxicity (Figure 1). There was no 238 
significant association between underlying cerebral comorbidities and cefepime 239 
neurotoxicity. ICU stay during hospitalisation and haematological malignancy were highly 240 
statistically significant associations for presumed neurotoxicity from the fitted multivariable 241 
adjusted logistic models (Tables S3 and 4). Figure S3 (supplementary material) depicts the 242 
variables that were independently associated with a higher probability of possible 243 
neurotoxicity according to the multivariate logistic regression. 244 
No patient developed possible neurotoxicity at cefepim  plasma trough concentrations < 7.7 245 
mg/L. The probability of neurotoxicity from the fitted logistic regression model was  25% for 246 
cefepime concentrations ≥ 12 mg/L  , 50% for cefepime concentrations ≥ 16 mg/L (Figure 247 
2)All patients had neurotoxicity at cefepime trough con entrations ≥ 38.1 mg/L . Sensitivity 248 
and specificity for each of the thresholds defined in Figure 2 is presented in Table S5, 249 
supplementary material. 250 
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Patients with presumed cefepime neurotoxicity had a significantly lower eGFR (35.0 251 
ml/min/1.73m2 [IQR 23.3,53.3]) when compared to patients without neurologic symptoms  252 
(82.0 ml/min/1.73m2 [IQR 45.0,105.0]), p<0.001  (Tables S3 and Table 2). Moreover, renal 253 
function was less frequently stable, and the cefepim  dose adjusted to renal clearance was 254 
significantly higher, in patients with presumed neurotoxicity. As expected, cefepime trough 255 
concentrations were inversely correlated with renal function (Figure S4, supplementary 256 
material). The highest proportion of patients with presumed cefepime neurotoxicity (31/57, 257 
54%) and in-hospital mortality (14/57,25%) was seen in patients with an eGFR < 258 
30mL/min/1.73m2 (Table 3). In-hospital mortality was significantly higher in patients with 259 
presumed cefepime neurotoxicity (7.8% vs 35.1%, p <0.001) (Table S4). The most frequent 260 
causes of death in these patients were their underlying conditions and infections (Table S4, 261 
supplementary material). 262 
 263 
Discussion  264 
In our study we found that there was no risk of developing neurotoxicity with cefepime 265 
plasma trough concentrations < 7.7 mg/L. However, all patients with concentrations above 266 
38.1 mg/L, presented with neurological symptoms. The relationship between cefepime 267 
plasma concentrations and risk of neurotoxicity has been evaluated in two other studies with 268 
substantially smaller patient numbers. Huwyler et al. [13] studied 93 hospitalised patients and 269 
stated that no neurotoxicity was seen at any sample concentration (trough, intermediate or 270 
steady-state) below 35mg/L. In addition, Lamoth et al.[14] evaluated 30 hospitalised patients 271 
with febrile neutropenia receiving high doses of ceepime. In their study, patients with 272 
cefepime plasma concentrations > 22 mg/L had a 50% probability of developing neurologic 273 
symptoms.  274 
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To our knowledge, the relationship between cefepime plasma concentrations and 275 
neurotoxicity has not been studied in such a large number of patients. In our cohort, the 50% 276 
probability of developing presumed neurotoxicity was reached at a lower concentration (≥ 16 277 
mg/L) than previously reported. Based on our current r sults, we would advise to target 278 
cefepime plasma trough concentrations at < 7.5 mg/L to avoid the risk of neurotoxicity in 279 
patients undergoing cefepime therapy. 280 
In our study 23.2% developed symptoms consistent with neurotoxicity. This is similar to the 281 
study of Lamoth et al. (20%) [14], but substantially higher than in the study of Huwyler et 282 
al.(11%) [13]. This difference might be due to the increased sensitivity for recognizing 283 
potential neurotoxicity by implementing a broader dfinition based on available literature and 284 
prescribing information (i.e. 3 patients with vertigo) [15, 17-19, 21].  In addition, the previous 285 
studies [13, 14] only included patients that develop d signs of neurotoxicity at least ≥ 2 days 286 
after start of cefepime treatment. Although penetration of cefepime into the central nervous 287 
system is not very high (approx. 5-10% of serum concentration in patients with intact blood 288 
brain barrier), concentrations in the cerebrospinal fluid (CSF) increase within hours after 289 
intravenous dosing [27]. In patients with renal faiure, penetration into CSF may be higher 290 
(up to 45%) [28], and very short latency periods of less than two days between start of 291 
cefepime treatment and neurological deterioration have been reported [10]. Including patients 292 
that had already developed neurological symptoms after 3 dose intervals of cefepime 293 
increased the sensitivity of detecting adverse neurological effects in our study.  294 
Patients with haematological malignancy and those who needed intensive care during 295 
hospitalisation, were at substantially higher risk of cefepime associated neurotoxicity. Latter 296 
is in line with the study of Huwyler et al. [13]. ICU patients are prone to disruptions of the 297 
blood-brain barrier, which might facilitate the CNS penetration of cefepime [15]. 298 
Furthermore, they have a high frequency of renal impairment.  299 
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The highest proportion of patients with suspected nurotoxicity was seen in those with an 300 
eGFR < 30ml/min/1.73m2. Moreover, the cefepime dose adjusted to the renal function was 301 
significantly higher in patients with presumed cefepime neurotoxicity. These patients also 302 
had higher cefepime plasma trough concentrations. As elimination of cefepime is primarily 303 
mediated by glomerular filtration in the kidneys [29, 30], reduced creatinine clearance has 304 
been shown to lead to drug accumulation [4] and thus igher probability of cefepime-305 
associated neurotoxicity [13-15, 17]. Consequently, we emphasize the importance of closely 306 
monitoring renal parameters and cefepime trough concentrations in patients with eGFR 307 
<60mL/min/1.73m2.   308 
 309 
No statistically significant difference was found in those with or without neurotoxicity in the 310 
use of confounding centrally-active co-medication at cefepime trough concentrations ≥ 311 
5mg/L.  It should however be taken into consideration hat central effects of these agents are 312 
dose-dependent. Due to the retrospective character of this study, doses of administered co-313 
medications were not considered.  314 
Surprisingly, we found no statistically significant association between underlying structural 315 
or functional cerebral impairments and the development of neurotoxicity; The incidence of 316 
neurotoxicity might be unrecognized and the causality is difficult to assign either to the 317 
underlying condition or cefepime treatment [15].  318 
Mortality was significantly higher in patients who presented signs of neurotoxicity compared 319 
to those without. To our knowledge, there is no other study with a similar design addressing 320 
this issue. Whether cefepime neurotoxicity had an impact on the patient’s outcome remains to 321 
be determined. Cefepime neurotoxicity is strongly associated with higher cefepime plasma 322 
concentrations due to declining renal function. Renal failure is a marker for more severe 323 
illness, e.g. multi-organ failure and severe sepsis. Since the causes of death among patients 324 
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with presumed neurotoxicity were non-neurologic in the majority of the cases, cefepime 325 
neurotoxicity may not be causally related to mortality, but rather be associated with more 326 
severe illness leading to lower eGFR.     327 
This study is limited by its retrospective nature and data was not specifically collected to 328 
depict the incidence of cefepime-induced neurotoxicity. However, we increased sensitivity 329 
for recognizing potential neurotoxicity by implementing a broader definition based on 330 
available literature and prescribing information. I addition, we did not only include patients 331 
with a delay of at least two days after start of the antibiotic, which may have increased 332 
sensitivity for detecting early manifestations of neurotoxicity, especially in those with renal 333 
failure.  However, at our institution, TDM is not routinely performed in all patients receiving 334 
cefepime, but mainly in those receiving high-dose cefepime treatment or with known renal 335 
insufficiency. Therefore, the proportion of patients presenting with neurotoxicity in this study 336 
probably overestimates the real incidence of neurotoxicity among patients treated with 337 
cefepime.  338 
Although we have taken into account many confounding parameters, plasma trough 339 
concentrations do not reflect pharmacodynamics and toxicodynamic interactions caused by 340 
individual and environment-related factors, which might be a limitation of this testing 341 
method.  342 
 343 
In conclusion, particular caution and a high index of suspicion of neurotoxicity is required for 344 
patients with renal insufficiency, multi morbidity and those in ICU care who are treated with 345 
cefepime. We advise  implementing TDM as a routine ool to guide therapy in those patients 346 
and to target cefepime trough concentrations ≤ 7.5mg/L. However, special attention should 347 
be paid to infections with pathogens that require higher dosage of cefepime in order to 348 
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prevent treatment failure and/or resistance evolution such  as infections with  pseudomonas 349 
aeruginosa that harbour cefepime MICs of 4- 8mg/L. 350 
Further prospective studies investigating the development of cefepime neurotoxicity in 351 
patients with cerebral comorbidities are needed in order to assess whether the use of cefepime 352 
is safe in these patients. Furthermore, we envisage ext rnally validating the thresholds 353 
presented here using data from other hospitals in a further study. 354 
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Table 1. Symptoms and Outcome of Patients with presumed Cefepime Neurotoxicity 
 
 N (%) 
Overall number of patients 74 
Standardised case causality assessment according to WHO-UMC  74 (100) 
Number of patients with following symptoms 
- Confusion, agitation, hallucinations 
- Reduced consciousness, coma 
- Myoclonus 
- Vertigo 
- Flapping tremor 
- Ataxia 
- Seizure, non-convulsive status epilepticus 
- Aphasia 
- Dystonia / dyskinesia 
 
46 (62) 
32 (43) 
6 (8) 
3 (4) 
2 (3) 
2 (3) 
2 (3) 
1 (1) 
1 (1) 
Median time from first cefepime dose to symptom presentation, days [range] 2 [1, 14] 
Number of patients (%) in whom cefepime was 
- Stopped  
- Adapted 
- Not modified 
After the occurrence of suspected neurotoxicity  
 
45 (61) 
26 (35) 
3 (4) 
Number of patients (%) with symptom improvement or resolution after stop of cefepime 60 (81) 
Median time to improvement or recovery after treatment adaptation, days [range] 2 [1, 19] 
WHO-UMC: World Health Organisation Uppsala Monitoring Centre  
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Table 2: Univariable and Multivariable Logistic Regression with the Variable for presumed 
Cefepime Neurotoxicity as Indicator Variable; Final Model for the Multivariate adjusted 
model. 
n.s, not significant at the 5% concentration; n.E., not estimated, yr, year; eGFR, estimated glomerular 
filtration rate; ICU, intensive care unit * collinear with cefepime trough concentration excluded from 
final model (tested using Farrar-Glauber test) 
 
 Univariate  Multivariate  
 Odds Ratio 
 [95% confidence interval] 
p-value Odds Ratio 
[95% confidence interval] 
p-value 
Cefepime plasma trough 
concentration, mg/L 
1.31 [1.24, 1.40] < 0.001 1.33 [1.23, 1.45] < 0.001 
Cefepime treatment 
duration until plasma 
trough concentration 
measurement, days 
0.99 [0.92, 1.05] 0.7 n.s - 
Adjusted cefepime dose, 
g/d per 100mL/min/1.73m2 
eGFR  
1.68 [1.48, 1.95] <0.001 1.39 [1.20, 1.64] <0.001 
Age, years (10 yr steps) 1.46 [1.18, 1.83] <0.001 n.s. - 
Male sex 0.71 [0.41, 1.24] 0.2 n.s. - 
ICU stay during 
hospitalisation 
2.45 [1.39, 4.52] 0.003 8.23 [2.87, 27.48] < 0.001 
eGFR, mL/min/1.73m2 (10 
unit steps) 
- Steady state 
0.71 [0.63, 0.78] 
 
0.19 [0.10, 0.34] 
< 0.001 
 
< 0.001 
* 
 
n.E. 
* 
General comorbidities  
- Overall 
- Cardiovascular 
- Pulmonary 
- Diabetes 
- Solid cancer 
- Haematological 
cancer 
 
1.61 [1.23, 2.12] 
2.06 [1.18, 3.68] 
1.84 [1.08, 3.23] 
1.47 [0.84, 2.54] 
0.96 [0.46, 1.90] 
 
2.06 [0.96, 4.25] 
 
<0.001 
0.01 
0.03 
0.2 
0.9 
 
0.06 
 
n.E. 
n.s. 
3.41 [1.28, 10.07] 
n.s. 
n.s. 
 
6.27 [1.62, 25.30] 
 
- 
- 
0.02 
- 
- 
 
0.008 
Cerebral comorbidities 
- Overall 
- Arterial or venous 
thrombosis, 
haemorrhage 
- Tumor 
- Epilepsy 
- Infection 
- Dementia, 
cognitive 
impairment 
- Other 
 
0.89 [0.60, 1.25] 
 
 
0.55 [0.25, 1.11] 
1.22 [0.33, 3.68] 
1.35 [0.47, 3.47] 
0.82 [0.23, 2.32] 
 
 
4.61 [0.99, 23.86] 
0.48 [0.11, 1.44] 
 
0.5 
 
 
0.1 
0.8 
0.6 
0.7 
 
 
0.05 
0.2 
 
n.E. 
 
 
n.s. 
n.s. 
n.s. 
n.s. 
 
 
n.s. 
n.s. 
 
- 
 
 
- 
- 
- 
- 
 
 
- 
- 
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Table 3: Cefepime Plasma Trough Levels, Doses, presumed Cefepime Neurotoxicity and 
Death according to Renal Function among all Patients (n = 319) 
 eGFR > 90mL/min 
 
60 < eGFR < 
90mL/min 
 
30 < eGFR < 
60mL/min 
 
eGFR <30mL/min 
 
Overall number of 
patients 
106 69 87 57 
Median cefepime 
plasma trough 
concentration, mg/L 
[IQR] 
5.6 [3.4, 7.7] 7.2 [5.3, 11.1] 11.6 [6.1, 21.9] 16.3 [7.1, 26.2] 
Median adjusted 
cefepime dose, g/d per 
100mL/min/1.73m2 
eGFR [IQR] 
3.0 [2.6, 4.9] 3.6 [2.9, 4.5] 4.7 [3.3, 6.3] 7.1 [4.4, 10.5] 
Neurotoxicity (%) 4 (4%) 11 (16%) 28 (32%) 31 (54%) 
Hospital mortality (%) 9 (9%) 3 (4%) 19 (22%) 14 (25%) 
eGFR, estimated glomerular filtration rate; IQR, interquartile range 
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Figure 1. Cefepime Plasma Trough Concentration for Patients with and without presumed 1 
Cefepime Neurotoxicity 2 
 3 
 4 
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Figure 2. Probability of Cefepime associated Neurotoxicity as a Function of Cefepime 1 
Plasma Trough Concentrations; Cut-off Thresholds for Neurotoxicity i.) 0% Neurotoxic 2 
below 7.7 mg/L (Green Solid Vertical Line), ii.) Probability of being Neurotoxic = 0.25 at 12 3 
mg/L (Grey Solid Line), and iii.) Probability of being Neurotoxic = 0.5 at 16 mg/L (Dashed 4 
Orange Lines), and iv.) 100% Neurotoxic above 38.1 mg/L (Solid Red Line); vertically 5 
jittered Data points to ease Readability. 6 
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